RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart failure is classified into two major clinical subtypes- heart failure with ...

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Parasitic worms are difficult to kill with current therapies, but their commensal bacteria might be their Achilles’ heel.

A new study has identified an enzyme that plays an important role in breaking down unneeded or damaged proteins in the heart -- an important process for maintaining heart health.

Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...